A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy

Translational Oncology

Volumn 2, Issue 3, 2009, Pages 184-190

  Galbán, Craig J ^a   Mukherji, Suresh K ^a   Chenevert, Thomas L ^a   Meyer, Charles R ^a   Hamstra, Daniel A ^a   Bland, Peyton H ^a   Johnson, Timothy D ^a   Moffat, Bradford A ^a   Rehemtulla, Alnawaz ^a   Eisbruch, Avraham ^a,b   Ross, Brian D ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Center for Molecular Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GADOLINIUM PENTETATE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EARLY DIAGNOSIS; HEAD AND NECK CANCER; HUMAN; PARAMETRIC TEST; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 77949630774     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09175     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Lemort M, Canizares AC, and Kampouridis S (2006). Advances in imaging head and neck tumours. Curr Opin Oncol 18, 234-239. (Pubitemid 43740417)
3. Srinivasan A, Dvorak R, Perni K, Rohrer S, and Mukherji SK (2008). Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 29, 40-44.
4. Srinivasan A, Dvorak R, Rohrer S, and Mukherji SK (2008). Initial experience of 3-tesla apparent diffusion coefficient values in characterizing squamous cell carcinomas of the head and neck. Acta Radiol 49, 1079-1084.
5. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, Zanzonico PB, et al. (2009). Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 11 (3), 247-259, 2p following 259.
6. Harisinghani M, Ross RW, Guimaraes AR, and Weissleder R (2007). Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9 (12), 1160-1165. (Pubitemid 350255363)
7. Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, Fulton SM, and Brindle KM (2009). A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 11 (6), 574-582, 1p following 582.
8. Young MR, Ileva LV, Bernardo M, Riffle LA, Jones YL, Kim YS, Colburn NH, and Choyke PL (2009). Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography. Neoplasia 11 (3), 237-246, 1p following 246.
9. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, et al. (2009). A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9 (12), 1003-1011. (Pubitemid 350255347)
10. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, et al. (2009). Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11 (2), 102-125.
11. Seierstad T, Folkvord S, Roe K, Flatmark K, Skretting A, and Olsen DR (2007). Early changes in apparent diffusion coefficient predict the quantitative anti-tumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia 9 (5), 392-400. (Pubitemid 46799982)
12. Wang J, Takashima S, Takayama F, Kawakami S, Saito A, Matsushita T, Momose M, and Ishiyama T (2001). Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220, 621-630. (Pubitemid 32799967)
13. Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, Vander Poorten V, Delaere P, and Hermans R (2007). Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 67, 960-971. (Pubitemid 46320065)
14. Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, and Poptani H (2009). Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 15, 986-994.
15. Szafer A, Zhong J, Anderson AW, and Gore JC (1995). Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed 8, 289-296.
16. Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3, 1457-1466.
17. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, et al. (2005). Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102, 5524-5529. (Pubitemid 40530291)
18. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, et al. (2005). Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102, 16759-16764. (Pubitemid 41688850)
19. Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, et al. (2008). Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26, 3387-3394.
20. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, and Ross BD (2006). The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8, 259-267.
21. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, et al. (2009). The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15, 572-576.
22. Pruessmann KP, Weiger M, Scheidegger MB, and Boesiger P (1999). SENSE: sensitivity encoding for fast MRI. Magn Reson Med 42, 952-962. (Pubitemid 29521486)
23. Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, Koral K, Frey KA, and Wahl RL (1997). Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1, 195-206.
24. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-2036. (Pubitemid 32045900)
25. Hamstra DA, Lee KC, Moffat BA, Chenevert TL, Rehemtulla A, and Ross BD (2008). Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 1, 187-194.
26. Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, et al. (2003). Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21, 1094-1100. (Pubitemid 46594139)
27. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, and Stopeck A (2004). Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6, 831-837. (Pubitemid 40041502)
28. Hamstra DA, Rehemtulla A, and Ross BD (2007). Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25, 4104-4109. (Pubitemid 47495868)
29. Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M, Dornfeld KJ, Lawrence TS, Chenevert TL, Ross BD, et al. (2004). The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10, 916-928. (Pubitemid 39429317)
30. DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D, Pfeiffer KP, Lukas P, and Judmaier W (2003). Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56, 958-965. (Pubitemid 36794026)
31. Kremser C, Judmaier W, Hein P, Griebel J, Lukas P, and de Vries A (2003). Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 179, 641-649. (Pubitemid 37101649)